N
VIRX

Nuveen’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Nuveen’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-143,473
Closed -$475K – 3526
2022
Q1 		$475K Buy
143,473
+1,544
+1% +$4.65K ﹤0.01% 3032
2021
Q4 		$479K Sell
141,929
-9,529
-6% -$50.8K ﹤0.01% 3082
2021
Q3 		$1.32M Buy
151,458
+3,724
+3% +$36.7K ﹤0.01% 2867
2021
Q2 		$1.68M Buy
+147,734
New +$1.48M ﹤0.01% 2790

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Nuveen's VIRX Position: Q2 2022 in Review

Nuveen sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 143,473 shares — an estimated $475K sold.

Nuveen first reported a position in VIRX in Q2 2021 and held it in 4 quarters. The position peaked at $1.68M in Q2 2021. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

  • Nuveen reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 143,473 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $475K.
  • Nuveen first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Nuveen's Viracta Therapeutics, Inc. Common Stock position peaked at $1.68M in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.